382 related articles for article (PubMed ID: 10400403)
1. Current concepts in the pharmacological management of obesity.
Carek PJ; Dickerson LM
Drugs; 1999 Jun; 57(6):883-904. PubMed ID: 10400403
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic options for the treatment of obesity.
Campbell ML; Mathys ML
Am J Health Syst Pharm; 2001 Jul; 58(14):1301-8. PubMed ID: 11471477
[TBL] [Abstract][Full Text] [Related]
4. Modern medical management of obesity: the role of pharmaceutical intervention.
Aronne LJ
J Am Diet Assoc; 1998 Oct; 98(10 Suppl 2):S23-6. PubMed ID: 9787732
[TBL] [Abstract][Full Text] [Related]
5. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
Astrup A; Lundsgaard C
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():29-34. PubMed ID: 9792479
[TBL] [Abstract][Full Text] [Related]
6. A benefit-risk assessment of sibutramine in the management of obesity.
Nisoli E; Carruba MO
Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
[TBL] [Abstract][Full Text] [Related]
7. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
Davis R; Faulds D
Drugs; 1996 Nov; 52(5):696-724. PubMed ID: 9118819
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological intervention: the antiobesity approach.
Rissanen A
Eur J Clin Invest; 1998 Sep; 28 Suppl 2():27-30. PubMed ID: 9777325
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for obesity.
Ioannides-Demos LL; Proietto J; McNeil JJ
Drugs; 2005; 65(10):1391-418. PubMed ID: 15977970
[TBL] [Abstract][Full Text] [Related]
10. Current pharmacological approaches to the treatment of obesity.
Hauner H
Int J Obes Relat Metab Disord; 2001 May; 25 Suppl 1():S102-6. PubMed ID: 11466601
[TBL] [Abstract][Full Text] [Related]
11. Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity.
Ryan DH
Endocrine; 2000 Oct; 13(2):193-9. PubMed ID: 11186220
[TBL] [Abstract][Full Text] [Related]
12. Combined drug treatment of obesity.
Atkinson RL; Blank RC; Loper JF; Schumacher D; Lutes RA
Obes Res; 1995 Nov; 3 Suppl 4():497S-500S. PubMed ID: 8697049
[TBL] [Abstract][Full Text] [Related]
13. Update on the pharmacotherapy of obesity.
Cerulli J; Lomaestro BM; Malone M
Ann Pharmacother; 1998 Jan; 32(1):88-102. PubMed ID: 9475827
[TBL] [Abstract][Full Text] [Related]
14. Drug treatment of obesity.
Bray GA
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Apr; 13(1):131-48. PubMed ID: 10932681
[TBL] [Abstract][Full Text] [Related]
15. The pharmacologic approach to the treatment of obesity.
Weiser M; Frishman WH; Michaelson MD; Abdeen MA
J Clin Pharmacol; 1997 Jun; 37(6):453-73. PubMed ID: 9208352
[TBL] [Abstract][Full Text] [Related]
16. Medical management of obesity.
Berke EM; Morden NE
Am Fam Physician; 2000 Jul; 62(2):419-26. PubMed ID: 10929704
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
18. Antiobesity pharmacotherapy in the management of type 2 diabetes.
Scheen AJ; Lefèbvre PJ
Diabetes Metab Res Rev; 2000; 16(2):114-24. PubMed ID: 10751751
[TBL] [Abstract][Full Text] [Related]
19. Drug strategies for the treatment of obesity.
Alemany M; Remesar X; Fernández-López JA
IDrugs; 2003 Jun; 6(6):566-72. PubMed ID: 12811679
[TBL] [Abstract][Full Text] [Related]
20. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
Richter WO
MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
